June 19th 2025
First-line systemic therapy plus radiation therapy improved PFS vs second-line systemic therapy with or without radiation in hepatocellular carcinoma.
Nivolumab/Cabozantinib Combo Yielded Efficacy in Renal Cell Carcinoma Regardless of Nephrectomy
September 17th 2021Patients with renal cell carcinoma experienced a better overall survival when treated with nivolumab plus cabozantinib regardless of whether or not they underwent a nephrectomy previously.
Pembrolizumab Plus Lenvatinib Combo Approved for Treatment of First-Line Advanced RCC
August 12th 2021The combination of pembrolizumab plus lenvatinib received approval by the FDA in the first-line setting for patients with advanced renal cell carcinoma following the results of the phase 3 CLEAR trial.
FDA Grants Priority Review to BLA for Adjuvant Pembrolizumab in Certain Cases of RCC After Surgery
August 10th 2021A priority review to a biologics license application has been granted by the FDA for adjuvant pembrolizumab in certain populations of patients with renal cell carcinoma who have undergone surgery.
Lenvatinib Plus Pembrolizumab Demonstrates Antitumor Activity, Maintains Safety in Metastatic RCC
July 28th 2021The combination of lenvatinib plus pembrolizumab showed antitumor activity and a manageable safety profile for treatment-naïve or previously treated patients with metastatic renal cell carcinoma.
Lenvatinib/Pembrolizumab Combo Improved Efficacy Over Sunitinib Across RCC Risk Groups
June 9th 2021Lenvatinib plus pembrolizumab was efficacious for patients with advanced renal cell carcinoma and performed well in subgroup analyses of International Metastatic Renal Cell Carcinoma Database Consortium risk categories and target kidney lesions.